{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:47:46Z","timestamp":1792640866837,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ccm.2019.05.004","type":"journal-article","created":{"date-parts":[[2019,7,31]],"date-time":"2019-07-31T10:11:26Z","timestamp":1564567886000},"page":"561-572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["Interstitial Lung Disease in Polymyositis and Dermatomyositis"],"prefix":"10.1016","volume":"40","author":[{"given":"Kathryn","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonye K.","family":"Danoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ccm.2019.05.004_bib1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ccm.2019.05.004_bib2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ccm.2019.05.004_bib3","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1067\/mjd.2002.120621","article-title":"Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?","volume":"46","author":"Sontheimer","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.004_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J\u00a0Intern Med"},{"issue":"9","key":"10.1016\/j.ccm.2019.05.004_bib5","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","article-title":"Anti-MDA5 and anti-TIF1-\u03b3 antibodies have clinical significance for patients with dermatomyositis","volume":"49","author":"Hoshino","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.ccm.2019.05.004_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jns.2018.12.040","article-title":"Myositis-specific autoantibodies in dermatomyositis\/polymyositis in patients with interstitial lung disease","volume":"397","author":"Li","year":"2019","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.ccm.2019.05.004_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","article-title":"Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"121","author":"Hozumi","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.ccm.2019.05.004_bib8","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.injr.2014.10.162","article-title":"Myositis-specific and myositis associated autoantibodies in Indian patients with inflammatory myositis","volume":"9","author":"Srivastava","year":"2014","journal-title":"Indian J Rheumatol"},{"issue":"02","key":"10.1016\/j.ccm.2019.05.004_bib9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1055\/s-0034-1371528","article-title":"Pulmonary manifestations of polymyositis\/dermatomyositis","volume":"35","author":"Hallowell","year":"2014","journal-title":"Semin Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.ccm.2019.05.004_bib10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00408-016-9896-x","article-title":"Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease","volume":"194","author":"Johnson","year":"2016","journal-title":"Lung"},{"issue":"6","key":"10.1016\/j.ccm.2019.05.004_bib11","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10067-009-1110-6","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"28","author":"Chen","year":"2009","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.ccm.2019.05.004_bib12","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ccm.2010.05.008","article-title":"Pulmonary manifestations of the idiopathic inflammatory myopathies","volume":"31","author":"Kalluri","year":"2010","journal-title":"Clin Chest Med"},{"issue":"44","key":"10.1016\/j.ccm.2019.05.004_bib13","doi-asserted-by":"crossref","first-page":"76129","DOI":"10.18632\/oncotarget.19050","article-title":"Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.004_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10067-018-4267-z","article-title":"Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies","volume":"38","author":"Zampeli","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.ccm.2019.05.004_bib15","doi-asserted-by":"crossref","first-page":"e0155381","DOI":"10.1371\/journal.pone.0155381","article-title":"Factors associated with interstitial lung disease in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2016","journal-title":"Plos One"},{"issue":"4","key":"10.1016\/j.ccm.2019.05.004_bib16","doi-asserted-by":"crossref","first-page":"e60442","DOI":"10.1371\/journal.pone.0060442","article-title":"Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome","volume":"8","author":"Hamaguchi","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.004_bib17","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/qjmed\/77.1.1019","article-title":"Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes","volume":"77","author":"Marguerie","year":"1990","journal-title":"QJM"},{"issue":"6","key":"10.1016\/j.ccm.2019.05.004_bib18","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies","volume":"138","author":"Connors","year":"2010","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.ccm.2019.05.004_bib19","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.rmed.2014.09.003","article-title":"Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type","volume":"108","author":"Johnson","year":"2014","journal-title":"Respir Med"},{"issue":"7","key":"10.1016\/j.ccm.2019.05.004_bib20","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3899\/jrheum.161480","article-title":"Clinical profiles and prognosis of patients with distinct antisynthetase antibodies","volume":"44","author":"Shi","year":"2017","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1016\/j.ccm.2019.05.004_bib21","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1445-5994.2010.02164.x","article-title":"Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies","volume":"41","author":"Dugar","year":"2011","journal-title":"Intern Med J"},{"issue":"6","key":"10.1016\/j.ccm.2019.05.004_bib22","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A\u00a0longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.ccm.2019.05.004_bib23","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.autrev.2012.01.006","article-title":"Comparison of long-term outcome between anti-Jo1- and anti-PL7\/PL12 positive patients with antisynthetase syndrome","volume":"11","author":"Marie","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.ccm.2019.05.004_bib24","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome","volume":"13","author":"Lega","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ccm.2019.05.004_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.rmed.2016.07.009","article-title":"Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome","volume":"118","author":"Zamora","year":"2016","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.004_bib26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients","volume":"73","author":"Aggarwal","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ccm.2019.05.004_bib27","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s10067-015-3023-x","article-title":"Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD)","volume":"34","author":"Rojas-Serrano","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.ccm.2019.05.004_bib28","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1136\/jclinpath-2014-202367","article-title":"Pulmonary pathologic manifestations of anti-glycyl-tRNA synthetase (anti-EJ)-related inflammatory myopathy","volume":"67","author":"Schneider","year":"2014","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.ccm.2019.05.004_bib29","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.4049\/jimmunol.162.4.2315","article-title":"Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease","volume":"162","author":"Hirakata","year":"1999","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"10.1016\/j.ccm.2019.05.004_bib30","doi-asserted-by":"crossref","first-page":"e0120313","DOI":"10.1371\/journal.pone.0120313","article-title":"Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis\/dermatomyositis-associated interstitial lung disease: a retrospective case control study","volume":"10","author":"Hozumi","year":"2015","journal-title":"Plos One"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.004_bib31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.amjms.2017.07.013","article-title":"Clinical heterogeneity of interstitial lung disease in polymyositis and dermatomyositis patients with or without specific autoantibodies","volume":"355","author":"Chen","year":"2018","journal-title":"Am J Med Sci"},{"issue":"3","key":"10.1016\/j.ccm.2019.05.004_bib32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3109\/14397595.2015.1091155","article-title":"Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52","volume":"26","author":"Yamasaki","year":"2015","journal-title":"Mod Rheumatol"},{"issue":"5","key":"10.1016\/j.ccm.2019.05.004_bib33","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.ccm.2019.05.004_bib34","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.ccm.2019.05.004_bib35","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/acr.22728","article-title":"Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis","volume":"68","author":"Moghadam-Kia","year":"2016","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.004_bib36","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.resinv.2016.08.007","article-title":"Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"55","author":"Yoshida","year":"2017","journal-title":"Respir Investig"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.004_bib37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10067-015-3139-z","article-title":"Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis","volume":"35","author":"Xu","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"3.4","key":"10.1016\/j.ccm.2019.05.004_bib38","first-page":"251","article-title":"Clinical characteristics of dermatomyositis\/polymyositis associated interstitial lung disease according to the autoantibody","volume":"65","author":"Kishaba","year":"2018","journal-title":"J\u00a0Med Invest"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.004_bib39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12890-015-0154-4","article-title":"Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?","volume":"15","author":"Ikeda","year":"2015","journal-title":"BMC Pulm Med"},{"issue":"6","key":"10.1016\/j.ccm.2019.05.004_bib40","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.resinv.2018.07.007","article-title":"Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis","volume":"56","author":"Sakamoto","year":"2018","journal-title":"Respir Invest"},{"issue":"3","key":"10.1016\/j.ccm.2019.05.004_bib41","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3109\/s10165-012-0663-4","article-title":"Anti-CADM-140\/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease","volume":"23","author":"Sato","year":"2013","journal-title":"Mod Rheumatol"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.004_bib42","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjd.14882","article-title":"Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with\u00a0dermatomyositis","volume":"176","author":"Matsushita","year":"2017","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.ccm.2019.05.004_bib43","doi-asserted-by":"crossref","first-page":"909","DOI":"10.6061\/clinics\/2013(07)04","article-title":"Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis","volume":"68","author":"Cruellas","year":"2013","journal-title":"Clinics (Sao Paulo)"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.004_bib44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/14397595.2017.1317377","article-title":"Anti-SS-A\/Ro antibody positivity as a risk factor for relapse in patients with polymyositis\/dermatomyositis","volume":"28","author":"Tatebe","year":"2018","journal-title":"Mod Rheumatol"},{"issue":"6","key":"10.1016\/j.ccm.2019.05.004_bib45","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.semarthrit.2011.09.008","article-title":"Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody","volume":"41","author":"Marie","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.ccm.2019.05.004_bib46","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00296-009-0884-9","article-title":"Characteristics of interstitial lung disease in SS-A positive\/Jo-1 positive inflammatory myopathy patients","volume":"29","author":"V\u00e1ncsa","year":"2009","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.ccm.2019.05.004_bib47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/08916930600623791","article-title":"In patients with antisynthetase syndrome the occurrence of anti-Ro\/SSA antibodies causes a more severe interstitial lung disease","volume":"39","author":"La Corte","year":"2006","journal-title":"Autoimmunity"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.004_bib48","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-2133.2009.09484.x","article-title":"Long-term outcome of patients with polymyositis\/dermatomyositis and anti-PM-Scl antibody","volume":"162","author":"Marie","year":"2010","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.ccm.2019.05.004_bib49","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1136\/ard.2006.052191","article-title":"Anti-signal recognition particle autoantibodies: marker of a necrotizing myopathy","volume":"65","author":"Hengstman","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ccm.2019.05.004_bib50","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1002\/art.30513","article-title":"Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients","volume":"63","author":"Marie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.ccm.2019.05.004_bib51","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00296-016-3571-7","article-title":"Outcome and prognostic factors in a French cohort of patients with myositis-associated interstitial lung disease","volume":"36","author":"Obert","year":"2016","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.ccm.2019.05.004_bib52","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ejrad.2014.11.026","article-title":"Interstitial lung disease in anti-synthetase syndrome: initial and follow-up CT findings","volume":"84","author":"Debray","year":"2015","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.ccm.2019.05.004_bib53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.rmed.2017.04.007","article-title":"The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies","volume":"127","author":"Tanizawa","year":"2017","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.004_bib54","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.resinv.2016.09.006","article-title":"Predictive factors for long-term outcome in polymyositis\/dermatomyositis-associated interstitial lung diseases","volume":"55","author":"Fujisawa","year":"2017","journal-title":"Respir Invest"},{"issue":"8","key":"10.1016\/j.ccm.2019.05.004_bib55","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.ejrad.2016.05.012","article-title":"Antisynthetase syndrome: pulmonary computed tomography findings of adult patients with antibodies to aminoacyl-tRNA synthetases","volume":"85","author":"Waseda","year":"2016","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.ccm.2019.05.004_bib56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejrad.2018.08.005","article-title":"Radiological images of interstitial pneumonia in mixed connective tissue disease compared with scleroderma and polymyositis\/dermatomyositis","volume":"107","author":"Yamanaka","year":"2018","journal-title":"Eur J Radiol"},{"issue":"9","key":"10.1016\/j.ccm.2019.05.004_bib57","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.rmed.2011.05.006","article-title":"High-resolution computed tomography (HRCT) features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody","volume":"105","author":"Tanizawa","year":"2011","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.ccm.2019.05.004_bib58","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.rmed.2013.01.014","article-title":"The prognostic value of HRCT in myositis-associated interstitial lung disease","volume":"107","author":"Tanizawa","year":"2013","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.ccm.2019.05.004_bib59","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.chest.2016.04.007","article-title":"Management of myositis-related interstitial lung disease","volume":"150","author":"Morisset","year":"2016","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.ccm.2019.05.004_bib60","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2169\/internalmedicine.37.669","article-title":"Clinical features of polymyositis\/dermatomyositis with steroid-resistant interstitial lung disease","volume":"37","author":"Takada","year":"1998","journal-title":"Intern Med"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.004_bib61","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/RHU.0000000000000487","article-title":"Effective use of calcineurin inhibitor in combination therapy for interstitial lung disease in patients with dermatomyositis and polymyositis","volume":"23","author":"Shimojima","year":"2017","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.004_bib62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/s10165-007-0553-3","article-title":"Step-up versus primary intensive approach to the treatment of interstitial pneumonia associated with dermatomyositis\/polymyositis: a retrospective study","volume":"17","author":"Takada","year":"2007","journal-title":"Mod Rheumatol"},{"issue":"6","key":"10.1016\/j.ccm.2019.05.004_bib63","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.rmed.2013.02.015","article-title":"A\u00a0retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis\/dermatomyositis","volume":"107","author":"Mira-Avendano","year":"2013","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.004_bib64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","article-title":"Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis","volume":"18","author":"Barba","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.004_bib65","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00296-015-3328-8","article-title":"Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease","volume":"36","author":"Go","year":"2015","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.004_bib66","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0012-3692(15)50949-5","article-title":"Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease","volume":"130","author":"Swigris","year":"2006","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.ccm.2019.05.004_bib67","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease","volume":"40","author":"Fischer","year":"2013","journal-title":"J\u00a0Rheumatol"},{"issue":"12","key":"10.1016\/j.ccm.2019.05.004_bib68","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s10067-015-3065-0","article-title":"The efficacy of tacrolimus in patients with refractory dermatomyositis\/polymyositis: a systematic review","volume":"34","author":"Ge","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.ccm.2019.05.004_bib69","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.3899\/jrheum.161217","article-title":"Myositis-associated interstitial lung disease: predictors of failure of conventional treatment and response to tacrolimus in a US cohort","volume":"44","author":"Sharma","year":"2017","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.004_bib70","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/rheumatology\/keu166","article-title":"The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis","volume":"54","author":"Kurita","year":"2014","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.004_bib71","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10067-014-2803-z","article-title":"Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review","volume":"34","author":"Ge","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.ccm.2019.05.004_bib72","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the treatment of Jo1 antibody\u2013associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response","volume":"43","author":"Bauhammer","year":"2016","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.ccm.2019.05.004_bib73","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.ccm.2019.05.004_bib74","doi-asserted-by":"crossref","first-page":"e0133702","DOI":"10.1371\/journal.pone.0133702","article-title":"Efficacy of rituximab in refractory inflammatory myopathies associated with anti- synthetase auto-antibodies: an open-label, phase II trial","volume":"10","author":"Allenbach","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ccm.2019.05.004_bib75","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00408-009-9146-6","article-title":"Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis\/dermatomyositis","volume":"187","author":"Suzuki","year":"2009","journal-title":"Lung"},{"issue":"2","key":"10.1016\/j.ccm.2019.05.004_bib76","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1378\/chest.10-0360","article-title":"Polymyositis associated with severe interstitial lung disease","volume":"139","author":"Bakewell","year":"2011","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.ccm.2019.05.004_bib77","first-page":"1682","article-title":"Intravenous immunoglobulin as potential adjunct therapy for interstitial lung disease","volume":"13","author":"Hallowell","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"10.1016\/j.ccm.2019.05.004_bib78","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10067-018-4353-2","article-title":"Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease","volume":"38","author":"Cobo-Ib\u00e1\u00f1ez","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.ccm.2019.05.004_bib79","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1365-2796.2011.02459.x","article-title":"KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis","volume":"271","author":"Fathi","year":"2011","journal-title":"J\u00a0Intern Med"},{"issue":"6","key":"10.1016\/j.ccm.2019.05.004_bib80","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/imj.12754","article-title":"Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study","volume":"45","author":"Chen","year":"2015","journal-title":"Intern Med J"},{"issue":"3","key":"10.1016\/j.ccm.2019.05.004_bib81","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s10067-017-3854-8","article-title":"Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study","volume":"37","author":"Nakazawa","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ccm.2019.05.004_bib82","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13075-017-1506-7","article-title":"The predictive prognostic factors for polymyositis\/dermatomyositis associated interstitial lung disease","volume":"20","author":"Sugiyama","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.ccm.2019.05.004_bib83","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10067-015-2866-5","article-title":"HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients","volume":"34","author":"Zou","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.ccm.2019.05.004_bib84","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s40064-015-1013-8","article-title":"Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study","volume":"4","author":"Ikeda","year":"2015","journal-title":"Springerplus"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523119300322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523119300322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:56:59Z","timestamp":1759453019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523119300322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0272523119300322"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2019.05.004","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interstitial Lung Disease in Polymyositis and Dermatomyositis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2019.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}